Moberg Pharma AB (publ) represents values of innovation, growth, and patient-centered care. With a strong corporate philosophy focused on developing and commercializing innovative pharmaceutical solutions, Moberg Pharma aims to improve the lives of patients worldwide. The company's core values drive their commitment to excellence, integrity, and sustainability. Moberg Pharma AB (publ) is dedicated to delivering high-quality products and driving long-term growth through strategic partnerships and expansion into new markets. By prioritizing patient needs and embracing innovation, Moberg Pharma aims to make a positive impact on global healthcare.

Moberg Pharma AB (publ) primarily operates in the United States, Sweden, and other key markets worldwide. With a global presence, the company focuses on offering innovative products across different regions to cater to the specific needs of consumers. The United States represents a significant market for Moberg Pharma AB (publ), where they have a strong presence and actively engage in expanding their market share. In Sweden, the company benefits from its home country advantage, leveraging its established presence and reputation. Additionally, Moberg Pharma AB (publ) extends its reach to other regions to maximize its international footprint and capture new growth opportunities.

Moberg Pharma AB (publ) has achieved several significant milestones. Firstly, they have successfully developed and commercialized numerous innovative pharmaceutical products in the dermatology field. Secondly, they have established strategic partnerships with major pharmaceutical companies, enhancing their market presence and distribution capabilities. Additionally, the company has expanded its product portfolio through acquisitions and successful licensing agreements. Moberg Pharma AB (publ) has also demonstrated strong financial performance, including revenue growth and profitability. Overall, their achievements showcase their dedication to advancing dermatology treatments and their commitment to delivering value to shareholders and stakeholders alike.

Moberg Pharma AB (publ) is a pharmaceutical company founded in 2006. Headquartered in Stockholm, Sweden, the company focuses on developing and commercializing innovative treatments for skin diseases and disorders. Moberg Pharma AB (publ) is known for its extensive portfolio of over-the-counter products and prescription medicines. The company has a strong track record of successfully launching and marketing its products globally. With a commitment to research and development, Moberg Pharma AB (publ) continues to collaborate with healthcare professionals to improve the lives of patients suffering from various dermatological conditions. With a dedicated team and a forward-thinking approach, Moberg Pharma AB (publ) is poised to remain a leader in the pharmaceutical industry.

The main competitors of Moberg Pharma AB (publ) in the market include companies like Johnson & Johnson, Pfizer Inc., GlaxoSmithKline, and Novartis AG. These companies operate in the pharmaceutical and healthcare industry, offering products and solutions that may compete with Moberg Pharma's portfolio. It is important for Moberg Pharma to stay innovative and differentiate itself from the competition in order to maintain its market position and attract investors.

Moberg Pharma AB (publ) is primarily active in the pharmaceutical industry.

Moberg Pharma AB (publ) operates with a business model focused on the development, marketing, and sales of innovative pharmaceutical products. The company specializes in finding solutions for various dermatological and podiatric conditions, offering both over-the-counter (OTC) and prescription treatments. Moberg Pharma AB (publ) aims to improve the quality of life for individuals suffering from conditions such as nail fungus, haemorrhoids, and skin irritations. By conducting extensive research and development activities, collaborating with partners, and targeting global markets, Moberg Pharma AB (publ) strives to provide effective and accessible treatments to a wide range of consumers.

Moberg Pharma AB (publ) hissesinin F/K oranı -20,64.

Moberg Pharma AB (publ) KUV 53,55 dir.

Moberg Pharma AB (publ) için AlleAktien Kalite Skoru 1/10'dur.

beklenen Moberg Pharma AB (publ) cirosu 9,09 Milyon. SEK dir.

beklenen Moberg Pharma AB (publ) karı -23,58 Milyon. SEK olarak gerçekleşmiştir.

Moberg Pharma AB (publ) is a publicly traded pharmaceutical company based in Sweden that focuses on the development, marketing, and sales of innovative over-the-counter products for the global market. The company is divided into three business areas: Consumer Health, Rx/Prescription, and Healthy Feet. The Consumer Health division is the largest and focuses on the development and marketing of OTC products for the self-medication market, including K4B and Emtrix. The Rx/Prescription division specializes in the development and marketing of prescription medications, such as MOB-015. The Healthy Feet division focuses on developing and marketing foot care and orthopedic products. Moberg Pharma prioritizes research and development and has partnerships with leading researchers and research institutions worldwide. The company operates in over 40 countries and has strong distribution and marketing structures in Europe and North America. Moberg Pharma aims to continually innovate and develop improved treatment options for patients worldwide.

Moberg Pharma AB (publ), yılda kez dağıtılmak üzere 0 SEK tutarında temettü ödemektedir.

Moberg Pharma AB (publ) için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Moberg Pharma AB (publ) şirketinin ISIN kodu SE0013121340’dir.

Moberg Pharma AB (publ) 'nin WKN'si A2PUSM 'dir.

Moberg Pharma AB (publ) için Ticker MOB.ST’dir.

Son 12 ay içerisinde Moberg Pharma AB (publ), tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Moberg Pharma AB (publ), tahmini olarak 0 SEK tutarında bir temettü ödemesi yapacak.

Moberg Pharma AB (publ) şirketinin mevcut temettü verimi .

Moberg Pharma AB (publ) dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Moberg Pharma AB (publ), son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 SEK tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Moberg Pharma AB (publ), 'Sağlık' sektörüne atanmıştır.

Son Moberg Pharma AB (publ) tarihinde 0 SEK tutarındaki en son temettüyü alabilmek için, hisseyi 24.10.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 24.10.2024 olarak gerçekleşti.

2023 yılında Moberg Pharma AB (publ) tarafından 0 SEK olarak temettüler dağıtıldı.

Moberg Pharma AB (publ) hisselerinin temettüleri SEK olarak dağıtılır.